Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Front Pharmacol ; 12: 775602, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34925034

RESUMO

Glioblastoma multiforme (GBM) is the most common and malignant brain tumor, and almost half of the patients carrying EGFR-driven tumor with PTEN deficiency are resistant to EGFR-targeted therapy. EGFR amplification and/or mutation is reported in various epithelial tumors. This series of studies aimed to identify a potent compound against EGFR-driven tumor. We screened a chemical library containing over 600 individual compounds purified from Traditional Chinese Medicine against GBM cells with EGFR amplification and found that cinobufagin, the major active ingredient of Chansu, inhibited the proliferation of EGFR amplified GBM cells and PTEN deficiency enhanced its anti-proliferation effects. Cinobufagin also strongly inhibited the proliferation of carcinoma cell lines with wild-type or mutant EGFR expression. In contrast, the compound only weakly inhibited the proliferation of cancer cells with low or without EGFR expression. Cinobufagin blocked EGFR phosphorylation and its downstream signaling, which additionally induced apoptosis and cytotoxicity in EGFR amplified cancer cells. In vivo, cinobufagin blocked EGFR signaling, inhibited cell proliferation, and elicited apoptosis, thereby suppressing tumor growth in both subcutaneous and intracranial U87MG-EGFR xenograft mouse models and increasing the median survival of nude mice bearing intracranial U87MG-EGFR tumors. Cinobufagin is a potential therapeutic agent for treating malignant glioma and other human cancers expressing EGFR.

2.
Acta Pharmacol Sin ; 30(11): 1559-65, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19890363

RESUMO

AIM: The role of CYP1A in the protection of aristolochic acid (AA)I-induced nephrotoxicity has been suggested. In the present study we investigated the effects of beta-naphthoflavone (BNF), a non-carcinogen CYP1A inducer, on AAI-induced kidney injury. METHODS: Mice were pretreated with 80 mg/kg BNF by daily intraperitoneal injection (ip) for 3 days followed by a single ip of 10 mg/kg AAI. AAI and its major metabolites in blood, liver and kidney, the expression of CYP1A1 and CYP1A2 in microsomes of liver and kidney, as well as the nephrotoxicity were evaluated. RESULTS: BNF pretreatment prevented AAI-induced renal damage by facilitating the disposal of AAI in liver. BNF pretreatment induced the expression of CYP1A1 in both liver and kidney; but the induction of CYP1A2 was only observed in liver. CONCLUSION: BNF prevents AAI-induced kidney toxicity primarily through CYP1A induction.


Assuntos
Ácidos Aristolóquicos/toxicidade , Nefropatias/prevenção & controle , beta-Naftoflavona/farmacologia , Doença Aguda , Animais , Ácidos Aristolóquicos/metabolismo , Citocromo P-450 CYP1A1/efeitos dos fármacos , Citocromo P-450 CYP1A1/metabolismo , Citocromo P-450 CYP1A2/efeitos dos fármacos , Citocromo P-450 CYP1A2/metabolismo , Indução Enzimática/efeitos dos fármacos , Injeções Intraperitoneais , Rim/efeitos dos fármacos , Rim/metabolismo , Nefropatias/induzido quimicamente , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Microssomos/efeitos dos fármacos , Microssomos/metabolismo , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/metabolismo
3.
Eur J Med Chem ; 44(4): 1410-4, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18996624

RESUMO

In an attempt to develop potent and selective antitumor agents, a series of 6- and 2-(1-substituted-thio-4-methylpent-3-enyl)-5,8-dimethoxynaphthalene-1,4-diones were designed and synthesized. The cytotoxicities of these compounds were evaluated in vitro against BEL-7402, HT-29 and SPC-A1 cell lines. The pharmacological results showed that most of the prepared compounds displayed the excellent selective cytotoxicity toward HT-29 cells. From the structure-activity relationships we may conclude that the introduction of a thioether functional group at the 1'-position in the side chain of shikonin is associated with an increase in cytotoxicity.


Assuntos
Antraquinonas/síntese química , Antraquinonas/farmacologia , Antineoplásicos/síntese química , Antineoplásicos/farmacologia , Antraquinonas/química , Antineoplásicos/química , Linhagem Celular Tumoral , Avaliação Pré-Clínica de Medicamentos , Ésteres/química , Humanos , Concentração Inibidora 50 , Especificidade por Substrato , Compostos de Sulfidrila/química , Sulfetos/química
4.
Sheng Wu Gong Cheng Xue Bao ; 22(3): 492-8, 2006 May.
Artigo em Chinês | MEDLINE | ID: mdl-16755933

RESUMO

The Yellow Fever (YF) vaccine, an attenuated yellow fever 17D (YF-17D) live vaccine, is one of the most effective and safest vaccines in the world and is regarded as one of the best candidates for viral expression vector. We here first reported in China the construction and characterization of the recombinant expression vector of yellow fever 17D which contained the proteinase 2A fragment of foot-and-mouth disease virus (FMDV). Three cDNA fragments representing the full-length YF-17D genome, named 5'-end cDNA (A), 3'-end cDNA (B) and middle cDNA (C), were obtained by reverse transcription polymerase chain reaction (RT-PCR), together with the introduction of SP6 enhancer, necessary restriction sites and overlaps for homologous recombination in yeast. Fragment A and B were then introduced into pRS424 in turn by DNA recombination, followed by transfection of fragment C and the recombinant pRS424 containing A and B (pRS-A-B) into yeast. A recombinant vector containing full length cDNA of YF-17D (pRS-YF) was obtained by screening on medium lack of tryptophan and uracil. A recombinant YF-17D expression vector containing FMDV-2A gene fragment (pRS-YF-2A1) was then constructed by methods of DNA recombination and homologous recombination in yeast described above. In vitro transcription of the recombinant vector pRS-YF-2A1 was then carried out and introduced into BHK-21 cells by electroporation. Results of indirect immunofluorescence assay (IFA) and titer determination showed a stable infectious recombinant virus was gotten, whose features such as growth curve were similar to those of the parental YF-17D. The results suggest that the recombinant vector pRS-YF-2A1, by introduction of heterogenous genes via 2A region, is potential to be an effective live vaccine expression vector.


Assuntos
Vírus da Febre Aftosa/genética , Vetores Genéticos , Vacinas Virais/genética , Animais , Linhagem Celular , Clonagem Molecular , Cricetinae , Epitopos/imunologia , Febre Aftosa/prevenção & controle , Vírus da Febre Aftosa/imunologia , Engenharia Genética , Recombinação Genética , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/metabolismo , Vacinas Atenuadas , Vacinas Virais/imunologia , Vírus da Febre Amarela/genética , Vírus da Febre Amarela/imunologia
5.
Artigo em Inglês | MEDLINE | ID: mdl-12232620

RESUMO

The increase of Lewis x and Sialyl Lewis x epitopes on the surface of cancer cells was known for decades. alpha(1,3) FuT is the key enzyme in the biosynthesis of these epitopes. The increase of the activity of this enzyme was actually found in many cancer tissues, cancer cell lines and the serum of the cancer patients. The recent cloning of the enzyme led to the possibility of the application of the sensitive methods with small amount of tissues to detect the expression of the gene. In this paper, probes for alpha(1,3) FuT type III, V and VI were prepared, and they are 447, 486 and 443 bp in length respectively. The DIG-labeled probe (type V) was used to detect the mRNA of the enzyme by in situ hybridization. Surgical samples from five patients with metastatic lesions, five cases without metastasis and two normal liver tissues from liver angioma patients were examined. The alpha(1,3) FuT mRNA level was highest in samples with the metasitatic lesion, and lowest in normal tissues and those of the original tumor lesion in them. The difference is very distinct. The possibility of the method to be used in evaluation the prognosis of the disease is discussed.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...